Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 15/20 | 1.00 |
| ▸ | MMP3 | P08254 | 7/20 | 1.00 |
| ▸ | MMP2 | P08253 | 7/20 | 1.00 |
| ▸ | MMP9 | P14780 | 7/20 | 1.00 |
| ▸ | MMP1 | P03956 | 6/20 | 1.00 |
| ▸ | MMP7 | P09237 | 4/20 | 1.00 |
| ▸ | MMP8 | P22894 | 4/20 | 1.00 |
| ▸ | MMP13 | P45452 | 4/20 | 1.00 |
| ▸ | MMP14 | P50281 | 4/20 | 1.00 |
| ▸ | ADAM10 | O14672 | 4/20 | 1.00 |
| ▸ | ADAM33 | Q9BZ11 | 2/20 | 0.68 |
| ▸ | MMP15 | P51511 | 1/20 | 0.68 |
| ▸ | MMP16 | P51512 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29732231 | 1.00 | ADAM17 (1.00) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL6350415 | 1.00 | ADAM17 (1.00) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL1021287 | 1.00 | ADAM17 (1.00) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL6681213 | 0.93 | ADAM17 (0.86) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL6681788 | 0.91 | ADAM17 (0.84) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL6685255 | 0.91 | ADAM17 (0.84) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL4193352 | 0.90 | ADAM17 (1.00) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL8282217 | 0.90 | ADAM17 (1.00) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL8354979 | 0.90 | ADAM17 (0.82) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL4207403 | 0.90 | ADAM17 (0.82) | ADAM17MMP3MMP2MMP9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156867-A1 | ENGINEERED IMMUNE CELL THERAPEUTICS AND METHODS OF USE | Catamaran Bio, Inc. | 2024-05-16 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | OTONOMY INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190307678-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2019-10-10 | — | — | US | disclosed |
| US-10272034-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-08-25 | — | — | US | disclosed |
| US-9132087-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9132087-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-8648119-B2 | Controlled release immunomodulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648119-B2 | Controlled release immunomodulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090297533-A1 | CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090297533-A1 | CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20050261762-A1 | Medical devices to prevent or inhibit restenosis | MEDTRONIC VASCULAR, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-20040006137-A1 | Asymmetric synthesis of amino-pyrrolidinones and a crystalline, free-base amino-pyrrolidinone | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | ADAM17 4144/4885MMP3 1890/4885MMP2 3093/4885 |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | ADAM17 2372/4885MMP3 1167/4885MMP2 1635/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADAM17 2372/4885MMP3 1167/4885MMP2 1635/4885 |
| US-20040006137-A1 | Asymmetric synthesis of amino-pyrrolidinones and a crystalline, free-base amino-pyrrolidinone | MMP8, MMP9, ADAM8 | ADAM17 5/4885MMP3 16/4885MMP2 7/4885 |
| US-20190307678-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADAM17 2372/4885MMP3 1167/4885MMP2 1635/4885 |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | ADAM17 2372/4885MMP3 1167/4885MMP2 1635/4885 |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | ADAM17 4156/4885MMP3 1558/4885MMP2 2730/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADAM17 2372/4885MMP3 1167/4885MMP2 1635/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | ADAM17 2372/4885MMP3 1167/4885MMP2 1635/4885 |
| US-10272034-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | ADAM17 2372/4885MMP3 1167/4885MMP2 1635/4885 |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | ADAM17 4156/4885MMP3 1558/4885MMP2 2730/4885 |
| US-20090297533-A1 | CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, CD74, TSLP | ADAM17 2535/4885MMP3 2519/4885MMP2 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.